This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mortimer, J. E Articles by Hutchins, K. S Search for Related Content PubMed Articles by Mortimer, J. E Articles by Hutchins, K. S Social Bookmarking                   What's this?

Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine

Sentara Cancer Institute, 600 Gresham Drive, Norfolk, Virginia 23507, USA

Mary Kay Lauman, RN

Sentara Cancer Institute, 600 Gresham Drive, Norfolk, Virginia 23507, USA

Benjamin Tan, MD

Sentara Cancer Institute, 600 Gresham Drive, Norfolk, Virginia 23507, USA

Cindy L Dempsey, PharmD

EPI-Q Inc., 17W727 Butterfield Road, Suites E-G, Oakbrook Terrace, Illinois 60181, USA

Alicia C Shillington, RN, MPH, PhD

EPI-Q Inc., 17W727 Butterfield Road, Suites E-G, Oakbrook Terrace, Illinois 60181, USA

Kellie S Hutchins, PharmD

EPI-Q Inc., 17W727 Butterfield Road, Suites E-G, Oakbrook Terrace, Illinois 60181, USA

Background. Capecitabine is a novel fluoropyrimidine administered orally for treatment of gastrointestinal and breast malignancies. Toxicity described with capecitabine includes hand-and-foot syndrome (HFS), a potentially painful inflammation of the hands and feet. Pyridoxine has been reported to produce improvement in HFS symptoms. We conducted our study to determine the incidence and severity of HFS symptoms in capecitabine patients and to assess the effects of pyridoxine administered as prophylaxis or treatment.

Patients and methods. We retrospectively reviewed 99 charts of capecitabine patients receiving pyridoxine and 99 charts of those who had not.

Results. Of the 99 pyridoxine patients, 73 (74%) received it as prophylaxis, with the remainder receiving pyridoxine as acute HFS treatment. The median number of capecitabine cycles administered was five, with first-reported HFS onset at cycle 2 in those receiving pyridoxine prophylaxis versus 1.5 in those not (P 5 0.06). Incidence was significantly associated with capecitabine dose, with 76% of patients experiencing HFS in the highest dose ranges compared with 40% in the lowest (P B 0.01). The data did not support that pyridoxine prophylaxis prevented overall HFS incidence in a greater proportion of patients compared with those who did not receive prophylaxis (60% versus 53%, respectively, P 5 NS). However, when used as treatment, a greater proportion of patients receiving pyridoxine reported symptom improvement compared with those not receiving the agent (65% versus 12%, P B0.001). No differences in 12-week tumor response were seen.

Conclusion. The data do not support the use of pyridoxine as prophylaxis as neither the incidence nor the severity of HFS was affected. Once HFS develops, however, pyridoxine may provide some relief of HFS symptoms. A controlled trial of capecitabine with and without pyridoxine seems warranted.

Key Words: capecitabine • hand-and-foot syndrome • pyridoxine • pyridoxine [prophylaxis] • pyridoxine [treatment]

Journal of Oncology Pharmacy Practice, Vol. 9, No. 4, 161-166 (2003)
DOI: 10.1191/1078155203jp116oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Anderson, A. Jatoi, C. Robert, L. S. Wood, K. N. Keating, and M. E. Lacouture Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs) Oncologist, March 1, 2009; 14(3): 291 - 302. [Abstract] [Full Text] [PDF]

				S. M Gressett, B. L Stanford, and F. Hardwicke Management of hand-foot syndrome induced by capecitabine Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 131 - 141. [Abstract] [PDF]